Lazard Asset Management LLC Acquires New Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Lazard Asset Management LLC acquired a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGOGet Rating) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,997 shares of the medical instruments supplier’s stock, valued at approximately $247,000.

Other large investors have also recently modified their holdings of the company. Polar Capital Holdings Plc grew its stake in AngioDynamics by 1,257.7% during the third quarter. Polar Capital Holdings Plc now owns 1,325,508 shares of the medical instruments supplier’s stock valued at $34,384,000 after acquiring an additional 1,227,882 shares in the last quarter. Tamarack Advisers LP grew its stake in AngioDynamics by 16.7% during the third quarter. Tamarack Advisers LP now owns 350,000 shares of the medical instruments supplier’s stock valued at $9,079,000 after acquiring an additional 50,000 shares in the last quarter. Invesco Ltd. grew its stake in AngioDynamics by 40.1% during the third quarter. Invesco Ltd. now owns 376,571 shares of the medical instruments supplier’s stock valued at $9,768,000 after acquiring an additional 107,690 shares in the last quarter. Geode Capital Management LLC grew its stake in AngioDynamics by 1.7% during the third quarter. Geode Capital Management LLC now owns 652,763 shares of the medical instruments supplier’s stock valued at $16,932,000 after acquiring an additional 10,916 shares in the last quarter. Finally, Cornerstone Investment Partners LLC bought a new stake in AngioDynamics during the fourth quarter valued at approximately $229,000. 93.91% of the stock is owned by institutional investors.

In related news, Director Wesley Johnson sold 6,201 shares of the company’s stock in a transaction on Monday, April 11th. The shares were sold at an average price of $23.00, for a total transaction of $142,623.00. Following the completion of the sale, the director now directly owns 80,003 shares in the company, valued at approximately $1,840,069. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Dave Helsel sold 3,513 shares of the company’s stock in a transaction on Thursday, April 28th. The shares were sold at an average price of $22.44, for a total transaction of $78,831.72. Following the sale, the senior vice president now owns 22,874 shares of the company’s stock, valued at $513,292.56. The disclosure for this sale can be found here. Insiders own 4.80% of the company’s stock.

Shares of ANGO opened at $18.69 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.61 and a current ratio of 2.59. AngioDynamics, Inc. has a fifty-two week low of $17.56 and a fifty-two week high of $32.00. The firm has a 50 day moving average price of $22.12 and a 200-day moving average price of $24.20.

AngioDynamics (NASDAQ:ANGOGet Rating) last announced its quarterly earnings data on Thursday, April 7th. The medical instruments supplier reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.04. The firm had revenue of $74.00 million during the quarter, compared to analyst estimates of $76.32 million. AngioDynamics had a negative net margin of 12.99% and a negative return on equity of 0.12%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.02 EPS. Equities analysts expect that AngioDynamics, Inc. will post -0.01 earnings per share for the current year.

Several brokerages have issued reports on ANGO. Zacks Investment Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating and set a $21.00 target price for the company. in a research report on Tuesday, March 8th. Canaccord Genuity Group lifted their target price on shares of AngioDynamics from $34.00 to $40.00 in a research report on Friday, April 8th. Finally, StockNews.com began coverage on shares of AngioDynamics in a research report on Thursday, March 31st. They set a “hold” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $32.50.

AngioDynamics Company Profile (Get Rating)

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.

Featured Stories

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGOGet Rating).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.